Transdermal delivery of drug avoids the first pass effect and provides greater and more prolonged levels of drug when compared to oral administration. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. It also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. It also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha (1)-adrenergic receptors resulting in sedation, muscle relaxation and hypotension. In this study, matrix-type transdermal patches containing prochlorperazine maleate were prepared using different ratios of methocel E15LV, eudragit RL 100 and polyvinyl pyrolidone by solvent evaporation technique. All transdermal patches were evaluated for thickness, percent flatness, moisture uptake, tensile strength, drug content, weight variation, area variation, folding endurance and drug release studies for 6 hours. Selected patches were studied for in-vitro drug release and diffusion through cellophane membrane for 6 hours. The results indicated that combination of methocel E15LV, Eudragit RL 100 and polyvinyl pyrolidone can be used in the design of transdermal drug delivery system for prochlorperazine maleate.
Loading....